A5045704541- Systemic Lupus Erythematosus Research
- Rheumatoid Arthritis Research and Therapies
- Monoclonal and Polyclonal Antibodies Research
- Platelet Disorders and Treatments
- Atherosclerosis and Cardiovascular Diseases
- Musculoskeletal synovial abnormalities and treatments
- Liver Diseases and Immunity
- Renal Diseases and Glomerulopathies
- Chronic Lymphocytic Leukemia Research
- Lymphoma Diagnosis and Treatment
- Gout, Hyperuricemia, Uric Acid
- T-cell and B-cell Immunology
- Systemic Sclerosis and Related Diseases
- Inflammatory Myopathies and Dermatomyositis
- Hepatitis C virus research
- Eosinophilic Disorders and Syndromes
- Diabetes and associated disorders
- Cytokine Signaling Pathways and Interactions
- Biosimilars and Bioanalytical Methods
- Salivary Gland Disorders and Functions
- Heparin-Induced Thrombocytopenia and Thrombosis
- Histiocytic Disorders and Treatments
- Immunodeficiency and Autoimmune Disorders
- Cutaneous lymphoproliferative disorders research
- Peripheral Neuropathies and Disorders
Peking University First Hospital
2016-2025
Peking University
2016-2025
National Clinical Research Center for Digestive Diseases
2024-2025
Johns Hopkins University
2017-2023
Hainan Medical College Hospital
2018
University of Baltimore
2017
Peking University People's Hospital
2016
Objective To describe the baseline characteristics of patients with positivity for antiphospholipid antibodies (aPLs) who were enrolled in an international registry, Antiphospholipid Syndrome (APS) Alliance Clinical Trials and International Networking (APS ACTION) clinical database repository, overall by laboratory subtypes. Methods The APS ACTION registry includes adults persistently had aPLs. We evaluated sociodemographic aPL‐related classification criteria “non‐criteria”) subgroups...
<h3>BACKGROUND:</h3> Noninvasive ventilation (NIV) is increasingly used during ventilatory support. Neurally-adjusted assist (NAVA) a mode of mechanical that can improve patient-ventilator interaction. We conducted meta-analysis to compare interaction and clinical outcomes between NAVA pressure support (PSV) in adult subjects NIV. <h3>METHODS:</h3> The PubMed, Cochrane Library, Web Science, OpenGrey, Embase databases were searched for appropriate trials comparing NIV-NAVA with NIV-PSV...
Abstract Objectives To assess the risk of flare in systemic lupus erythematosus (SLE) patients after low-dose glucocorticoid (GC) discontinuation and to evaluate factors flare. Methods SLE who ever discontinued GCs were identified from Peking University First Hospital cohort. The disease profile GC was analysed. rate analysed using Kaplan–Meier analysis. Cox regression used determine effects variables on A prognostic nomogram proportional hazards modelling developed. Results total 132...
Abstract Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease associated with B‐cell hyperactivity. Telitacicept transmembrane activator, calcium modulator, and cyclophilin ligand interactor‐Fc fusion protein, which can neutralize both lymphocyte stimulator proliferation‐inducing ligand. Patients active SLE who received telitacicept were prospectively followed at month 1, 3, 6, 9, 12 after initiation. Thirty‐seven participants involved for 6.00 [3.00, 6.00] months. SRI‐4...
Objectives To investigate the mortality and causes of death in Chinese patients with systemic lupus erythematosus. Methods We collected clinical data all consecutive adult erythematosus at Rheumatology department Peking University First Hospital between January 2007 December 2015. The primary were identified, standardized ratio years life lost calculated, survival variables associated determined by Kaplan–Meier Cox regression analysis respectively. Results mean age 911 (814 females 97 males)...
Objective Although systemic lupus erythematosus ( SLE ) is the most common autoimmune disease associated with antiphospholipid antibodies aPL ), limited data exist regarding impact of on clinical phenotype ‐positive patients. The primary objective this study was to compare clinical, laboratory, and treatment characteristics patients those without SLE. Methods A secure web‐based capture system used store patient demographic ‐related laboratory characteristics. Inclusion criteria included...
Objectives To describe the outcomes of pregnancies in antiphospholipid antibody (aPL)-positive patients since inception AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking Registry. Methods We identified persistently aPL-positive recorded as ‘pregnant’ during prospective follow-up, defined ‘aPL-related outcome’ a composite of: (1) Preterm live delivery (PTLD) at or before 37th week due to pre-eclampsia (PEC), eclampsia, small-for-gestational age (SGA) and/or...
Objective To evaluate the subsequent rate of thrombosis among women with obstetric antiphospholipid syndrome (Ob‐ APS ) in a multicentre database antibody ( aPL )‐positive patients, and clinical utility adjusted Global Antiphospholipid Syndrome Score aGAPSS ), validated tool to assess likelihood developing new thrombosis, this group patients. Design Retrospective study. Setting The Alliance for Clinical Trials International Networking Database Repository. Population Women Ob‐ . Methods...
This study aimed to use cluster analysis (CA) identify different clinical phenotypes among antiphospholipid antibodies (aPL)-positive patients.The Alliance for Clinical Trials and International Networking (APS ACTION) Registry includes persistently positive aPL of any isotype based on the Sydney syndrome (APS) classification criteria. We performed CA baseline characteristics collected retrospectively at time registry entry first 500 patients included in registry. A total 30 data points were...
Objective To unravel the dynamical trajectory and features of glucocorticoids (GC) tapering discontinuation in patients with rheumatoid arthritis (RA) commencing GC concomitant conventional synthetic disease-modifying antirheumatic drugs (csDMARDs). Methods We used data from longitudinal real-world Treat-to-TARget RA cohort. Patients who started contaminant csDMARDs therapy were included. The changes dose disease activity evaluated. rate was analysed using Kaplan-Meier analysis. relapse...
Objectives To identify predictors and barriers to achieving remission in systemic lupus erythematosus (SLE) patients after attaining Lupus Low Disease Activity State (LLDAS). Methods This study included from the Sle TARget (STAR) cohort who did not fulfill LLDAS at baseline. The Kaplan-Meier method was used estimate cumulative probabilities of or flare attainment. Univariate multivariable Cox proportional hazards models were employed time remission. Barriers impeding achievement also...
ABSTRACT Objective To explore organ damages and factors associated with the occurrence of in Chinese patients systemic lupus erythematosus (SLE). Methods A cross‐sectional study was performed SLE a disease duration over 6 months at enrollment. The demographics, clinical characteristics, medication history were collected. profile damage measured by index (SDI) enrollment displayed. analyzed logistic regression analysis. Results Three hundred fifty enrolled this study. Their mean age 38.8 ±...
Abstract The aim of our study was to compare the performance ultrasonography (US) and dual-energy computed tomography (DECT) in detecting crystal deposition at lower extremity joints patients with gout. correlation imaging findings microscopic further assessed whenever aspiration is available. We recruited consecutive who were presented arthritis from January 2012 December 2014. All underwent DECT US scan bilateral knees, ankles, feet. Synovial fluid obtained by an acute inflammatory joint...
To investigate the frequency and determinants of flare in Chinese patients with lupus, focusing on effect glucocorticoid (GC) tapering who achieved low disease activity or remission.We collected baseline follow-up data from all consecutive a prospective lupus cohort between January 2017 December 2020. We defined using status (LLDAS), applied DORIS (Definitions Remission SLE) for remission criteria then assessed SELENA-SLEDAI Flare Index.Among total 185 enrolled, 139 exhibited median 29.8...
Abstract Objectives Our primary objective was to quantify damage burden measured by Damage Index for Antiphospholipid Syndrome (DIAPS) in aPL-positive patients with or without a history of thrombosis an international cohort (the APS ACTION cohort). Secondly, we aimed identify clinical and laboratory characteristics associated patients. Methods In this cross-sectional study, analysed the baseline classification. We excluded other autoimmune diseases. demographic, based on two subgroups: (i)...